pemetrexed,carboplatin,paclitaxel,vinorelbine,nivolumab,cisplatin,docetaxel,gemcitabine,ipilimumab,pembrolizumab
merck,bms
[]
 agree with you. it s a sad situation that pharma owns almost all the data to help us figure out better therapeutic allocation. it is now our job as academics to define those patients who need more and those who need less or none at all.
Medical Director of the McGill Thoracic Oncology Program; Chest surgeon; Neutrophil biologist; Cancer immunologist; Aspiring farmer